Sequenom Laboratories Announces National Coverage Agreement With UnitedHealthcare Insurance Company For Prenatal Diagnostic Testing Services

SAN DIEGO, Sept. 17, 2015 Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today that it has signed a national agreement with UnitedHealthcare Insurance Company, effective October 1, 2015, covering 43 million people throughout the United States, to provide the MaterniT21® PLUS, HerediT® CF Carrier Screen and HerediT® UNIVERSAL Carrier Screen laboratory-developed tests (LDT). The addition of this contract brings the number of covered lives under agreement by Sequenom Laboratories' diagnostic services to more than 200 million.

Published: 17 September 2015
Written by Editor
Nasdaq   Up on News   Projec Update  
Read more: Sequenom Laboratories ( SQNM )

LED Medical Diagnostics' VELscope(R) Vx Receives Regulatory Approval for Distribution in China

Approval Expands Global Market Reach of Award-Winning VELscope Vx System

VANCOUVER, BC--(Marketwired - September 09, 2015) - LED Medical Diagnostics Inc. ("LED Medical" or "the Company") (TSX VENTURE: LMD) (LEDIF) (LME.F) and its subsidiary LED Dental have received regulatory approval for the distribution of the VELscope® Vx Enhanced Oral Assessment System in China, opening up a large new market for the award-winning adjunctive screening device. Geneformation Technology, a distributor of laboratory equipment and consumables with offices in China, Hong Kong and the United States, has worked closely with the Company to obtain regulatory approval for the VELscope Vx from the China Food and Drug Administration. As of August 6, 2015, the VELscope Vx Enhanced Oral Assessment System is approved for sale in China as a medical apparatus, Category I, under approval number "国械备20151176."

Published: 09 September 2015
Written by Editor
Up on News   Project Update   TSXV  
Read more: LED Medical Diagnostics Inc ( LMD )

Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of Leukodystrophy

New Test is Most Comprehensive for Definitive Diagnosis of These Devastating Genetic Disorders

OMAHA, Neb.- Transgenomic, Inc. (TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the launch of the Transgenomic Leukodystrophy NGS Panel for the diagnosis of leukodystrophy, a group of rare progressive genetic disorders that affect the central nervous system by disrupting the growth or maintenance of the myelin sheath insulating nerve cells.

Leukodystrophies have typically been difficult to diagnose, with definitive diagnoses taking years of testing. Previously, brain MRI scans were commonly used, but often provided non-specific results.

Published: 14 July 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Transgenomic Inc ( TBIO)

Great Basin Announces Commercial Launch of Group B Strep Molecular Test

Company Secures More than 40 Evaluations since Launch

SALT LAKE CITY-- Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today its Group B Streptococcus (GBS) test—which received U.S. Food and Drug Administration (FDA) clearance in April—is now available to hospitals and laboratories in the U.S. Two laboratories have already converted their Group B Strep testing to Great Basin’s molecular test, and as of July 7, more than 40 sites are in active evaluation or scheduled to evaluate the sample-to-result test for GBS. Further, the Company announced its customers evaluating the test are forecasting usage of the GBS test at volumes 50 percent greater than their usage of the Company’s C. diff test.

Published: 08 July 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Great Basin Scientific Inc ( GBSN )

Photo Release -- Nasdaq Welcomes Natera Inc. to the Nasdaq Stock Market

NEW YORK, July 02, 2015 - Nasdaq (NDAQ) announced that trading of Natera, Inc. (NTRA) commenced on The Nasdaq Stock Market on July 2, 2015.

A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f235ba27-78c3-4042-b5f8-e2637f6eddd6

Natera is a leading genetic testing company that develops non-invasive methods for analyzing DNA. Natera’s team of PhDs and engineers uses its complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions.  Natera’s goal is to change the management of genetic disease worldwide, giving patients and providers essential health information.

Published: 02 July 2015
Written by Editor
Nasdaq   Up on News   New Listing  
Read more: Natera Inc ( NTRA )
  1. Signal Genetics Inc ( SGNL )
  2. Transgenomic Inc ( TBIO )
  3. Great Basin Scientific Inc ( GBSN )
  4. Miraculins Inc ( MOM )
  5. Biocept Inc ( BIOC )